Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ian McDonald
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 26
- Beta
- 0.09
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 167.01
Financials
Net Income
$-2.46MEBITDA
$-11.71MFree Cash Flow
$-8.42MEPS (diluted)
$-0.26Shares Outstanding (diluted)
9.83M+749.2%Operating Expenses
$11.71MCash & Debt
$308.33MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-12.23M | $-1.78 |
| 2024 | $0.00 | $-2.80M | $-0.65 |
| 2023 | $0.00 | $-7.37M | $-1.98 |
| 2022 | $0.00 | $-14.96M | $-6.15 |
| 2021 | $0.00 | $-8.65M | $-4.74 |
| 2020 | $0.00 | $-480.4K | $-0.38 |
| 2019 | $0.00 | $-236.2K | $-0.06 |
Valuation
DRUGhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60-33.33%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·5d ago·Negative
…ciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a clinical stage biotechnology company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that it will participate in the Founda…
View source ↗ - Newsglobenewswire.com·31d ago·Negative
…nces to Present at Upcoming Conferences NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences: EVENT: Cantor Global Healthcare Co…
View source ↗ - Newszacks.com·39d ago·Neutral
What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now? Does Bright Minds Biosciences Inc. (DRUG) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - Newszacks.com·40d ago·Negative
Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High? The average of price targets set by Wall Street analysts indicates a potential upside of 97% in Bright Minds Biosciences Inc. (DRUG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
View source ↗ - Newszacks.com·56d ago·Negative
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet The mean of analysts' price targets for Bright Minds Biosciences Inc. (DRUG) points to a 97.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
View source ↗
Earnings
Tue, Dec 22(in 3 months)
Consensus estimate $-1.12 per share
Typical surprise +27.1% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 17$-0.17 vs $-1.22beat
- Wed, May 20$-0.80 vs $-1.06beat
- Thu, Feb 12$-0.70 vs $-0.98beat
- Tue, Dec 23$-0.41 vs $-0.56beat
- Thu, Aug 14$-0.53 vs $-0.59beat
- Thu, May 15$-0.29 vs $-0.39beat
Estimates and results for DRUG via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DRUG officers and directors.
- Bought
- $7.2m
- Sold
- $9.8m
12 trades
1 trade
- Cormorant Asset Management, Lpsold
- Cormorant Asset Management, Lpbought
- Cormorant Asset Management, Lpbought
- Cormorant Asset Management, Lpbought
- Cormorant Asset Management, Lpbought
- Cormorant Asset Management, Lpbought
- Cormorant Asset Management, Lpbought
- Cormorant Asset Management, Lpbought
1 further Form 4 entry is share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in DRUG.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.